Longeveron LGVN 深 滬

Longeveron (LGVN) Shares Slide 59% After Hours: Here's Why

Longeveron Inc (NASDAQ:LGVN) shares fell 59.58% to $2.70 in after-hours trading Wednesday after the company announced topline results from its Phase 2b ELPIS II clinical trial evaluating laromestrocel as a potential treatment for hypoplastic left heart syndrome. Longeveron is a clinical-stage biotec...

09-17 13:59

Longeveron Announces Phase 2b ELPIS II Trial Of Laromestrocel In Hypoplastic Left Heart Syndrome Misses Primary Efficacy Endpoint; Initiates Cost-Optimization Measures To Maximize Shareholder Value

The top line results showed that the ELPIS II trial did not meet its primary endpoint of improvement in right ventricular ejection fraction (RVEF) at month 12, but there were exploratory clinical endpoints that the Company is continuing to analyze and plans to discuss with the FDA to determine a pot...

09-17 05:28

Longeveron Regains Nasdaq Compliance With Minimum Bid Price

The latest update is out from Longeveron ( ($LGVN) ). Longeveron Inc. disclosed...

09-15 04:27

Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference

09-03 13:15

Dick's Sporting Goods, Intuit And 3 Stocks To Watch Heading Into Tuesday

With U.S. stock futures trading mixed this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Dick’s Sporting Goods Inc. (NYSE:DKS) to post quarterly earnings of $3.77 per share on revenue of $5.65 billion before the opening bell, according ...

08-25 16:02

Longeveron Announces 1-for-10 Reverse Stock Split, Expected To Become Effective August 26

Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company will undertake a 1-for-10 reverse split of the Company’s Class A common stock, par value $0.00...

08-25 04:07

Longeveron Announces 1-for-10 Reverse Stock Split

Longeveron Inc. (NASDAQ: LGVN) announced a 1-for-10 reverse stock split to increase its share price and regain compliance with Nasdaq’s $1.00 minimum bid requirement. Effective August 26, 2026, the split aims to align the company’s share structure with future opportunities and institutional investor preferences. CEO Stephen Willard emphasized that the reverse split is a structural adjustment without altering the company’s strategy or operations. ...

08-24 20:05

Longeveron Inc. Earnings Call: Trials, Cash and Risk

Longeveron Inc. (($LGVN)) has held its Q2 earnings call. Read on for the main h...

08-23 08:25

Longeveron Appoints Nirav Jhaveri CFO, Succeeding Marie Washburn

Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Nirav Jhaveri, CFA, to the Company’s executive leadership team in the role of Ch...

08-20 04:07

Longeveron Appoints Nirav Jhaveri as Chief Financial Officer

Longeveron Inc. appoints Nirav Jhaveri as Chief Financial Officer, bringing over 25 years of experience in biotech finance and capital markets. Jhaveri succeeds Marie Washburn, who returns to her role as Corporate Controller. The company highlights Jhaveri's expertise in advancing stem cell therapy, particularly its lead product laromestrocel, which is in Phase 2b trials for HLHS. Jhaveri aims to support the company's growth and operational effic...

08-19 20:05